Biogen Inc. shares were on track for their biggest gain on record after the drugmaker released pricing for its recently approved Alzheimer’s drug Aduhelm.
May I point out that this drug failed one of two controlled trials and was approved under "fast track" authority anyway?
Of course Dr. Siegel thinks this is the best thing since sliced bread.
But.... while there are claims that this drug helps to remove and prevent the proteins in the brain that are linked to Alzheimer's the problem is that when a trial on a drug of this sort fails you have to step back. Is it worthless or worthwhile? Nobody really knows nor do we know much of anything about the side effects as they've not been published. Indeed there's plenty of debate over whether the "plaques" seen in Alzheimer's patients is the cause of the brain dysfunction or whether it's a biological result of what causes the dysfunction. In the latter case the drug will not work since that's not the actual problem, of course.
But what we do know is that this "accelerated approval" will make Biogen a hell of a lot of money whether the drug works or not.
And if you get the side effects? Sucks to be you, I suppose.
We haven't seen anything like that in the recent past out of the FDA, have we?